BioLineRx Raises $3.75M in Registered Direct Offering at $2.78/ADS
BLRX sits 33% above its 52-week low of $2.15 on light trading volume (0.1× avg).
Summary
BioLineRx priced a registered direct offering of 1.35M ADSs at $2.78, a 3% discount to the last close, raising $3.75M before fees. The deal includes warrants for up to 2.02M additional ADSs at the same price, plus an amendment to existing warrants lowering their exercise price to $2.78 and extending maturity to 2031. For a company with a market cap around $13M, this financing is highly dilutive—the warrant overhang alone could nearly triple the share count if exercised. Proceeds are earmarked for R&D and working capital, reflecting ongoing cash needs as GLIX1 advances through Phase 1/2a. The pricing at a modest discount and the warrant sweeteners suggest weak demand, a negative signal for near-term sentiment. Closing is expected August 31, 2026.
At the time of this announcement, BLRX was trading at $2.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $2.15 to $4.56. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.